Home Hepatorenal syndrome
Article
Licensed
Unlicensed Requires Authentication

Hepatorenal syndrome

  • Selda Demırtaş , Murat Can and Ayşegül Yarpuzlu
Published/Copyright: April 7, 2006
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 44 Issue 4

Abstract

This article summarizes the literature on current definition, suggested pathogenetic mechanisms and the role of laboratory assessment in the differential diagnosis of hepatorenal syndrome (HRS) from other causes of renal disease that may arise during hepatic cirrhosis and some diseases affecting both liver and kidney. It should be remembered that the main theory suggested for the pathogenesis of HRS is the arterial vasodilation hypothesis of portal hypertension, ending in type 1 and type 2 HRS, but there is no consensus supporting either mechanism as a solid theory for initiation of HRS pathogenesis to date. No laboratory test can firmly establish a diagnosis of HRS, which is mainly based on the absence of any specific cause of renal failure. Laboratory and ultrasonographic tests based on non-invasive techniques are being investigated as possible diagnostic approaches.

Keywords: cystatin C; hepatorenal syndrome; laboratory assessment
Corresponding author: Murat Can, Karaelmas University, Faculty of Medicine, Department of Biochemistry, Zonguldak, Turkey Phone: +90-372-2610169, Fax: +90-372-2610155

References

1. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49:729–37.10.1136/gut.49.5.729Search in Google Scholar

2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164–76.10.1002/hep.510230122Search in Google Scholar

3. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229–36.10.1016/0016-5085(93)90031-7Search in Google Scholar

4. Badalamenti S, Graziani G, Salerno F, Ponticello C. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Arch Intern Med 1993; 153:1957–67.10.1001/archinte.1993.00410170025003Search in Google Scholar

5. Rhodes J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 1975; 51:492–7.10.1136/pgmj.51.598.492Search in Google Scholar

6. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997; 17:233–47.10.1055/s-2007-1007201Search in Google Scholar

7. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97:2046–50.10.1111/j.1572-0241.2002.05920.xSearch in Google Scholar

8. Bilotta J, Pazik M, Greizersen H, Acara M. Renal effect of ethanol in isolated perfused rat kidney. Eur J Pharmacol 1984; 98:109–12.10.1016/0014-2999(84)90114-6Search in Google Scholar

9. Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77:215–22.10.1016/0016-5085(79)90268-3Search in Google Scholar

10. Epstein M. Renal prostaglandins and the control of renal function in liver disease. Am J Med 1986; 80:46–55.10.1016/0002-9343(86)90931-9Search in Google Scholar

11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151–7.10.1002/hep.1840080532Search in Google Scholar

12. Arroyo V, Guevera M, Gines P. Hepatorenal syndrome: pathogenesis and treatment. Gastroenterology 2002; 122:1658–76.10.1053/gast.2002.33575Search in Google Scholar

13. Colombato L, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1991; 15:323–8.10.1002/hep.1840150224Search in Google Scholar

14. Gines P, Martin PY, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int 1997; 51(Suppl):S77–82.Search in Google Scholar

15. Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Volkl H, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991; 14:590–4.10.1002/hep.1840140403Search in Google Scholar

16. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991; 337:776–8.10.1016/0140-6736(91)91384-7Search in Google Scholar

17. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balazo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139–41.10.1002/hep.1840180520Search in Google Scholar

18. Sogni P, Garnier P, Gadano A, Moreau R, Dall'Ava Santucci J, Dinh-Xuan AT, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995; 23:471–3.10.1016/0168-8278(95)80207-XSearch in Google Scholar

19. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl Med 1991; 329:2002–12.Search in Google Scholar

20. Pizcueta MP, Pique JM, Fernandez M, Bosch J, Rodes J, Whittle BJ, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103:1909–15.10.1016/0016-5085(92)91451-9Search in Google Scholar

21. Forrest EH, Jones AL, Dillon JF, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood in patients with cirrhosis. J Hepatol 1995; 23:254–8.10.1016/0168-8278(95)80468-4Search in Google Scholar

22. Hu LF, Sealey JE, Chen R, Zhou Y, Merali C, Shi YX, et al. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am J Hypertens 2004; 17:395–403.10.1016/j.amjhyper.2004.01.003Search in Google Scholar PubMed

23. Garcia-Estan J, Atucha NM, Sabio JM, Vargas F, Quesda T, Romero JC. Increased endothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 1994; 267:549–53.10.1152/ajpregu.1994.267.2.R549Search in Google Scholar

24. Moore K, Ward P, Taylor G, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100:1069–77.10.1016/0016-5085(91)90284-RSearch in Google Scholar

25. Guarner C, Colina I, Guarner F, Corzo J, Prieto J, Vilardell F. Renal prostaglandins in cirrhosis of the liver. Clin Sci 1986; 70:477–84.10.1042/cs0700477Search in Google Scholar

26. Laffi G, La Villa G, Pinzani M, Ciabattoni G, Patrignani P, Mannelli M, et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 1986; 90:274–82.10.1016/0016-5085(86)90921-2Search in Google Scholar

27. Rimola A, Gines P, Arroyo V, Camps J, Perez Ayuso RM, Quintero E, et al. Urinary excretion of 6-ketoprostaglandin F1-alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional renal failure(hepatorenal syndrome). J Hepatol 1986; 3:111–7.10.1016/S0168-8278(86)80154-4Search in Google Scholar

28. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-del-Arbol L, Gines P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41:579–87.10.1002/hep.20595Search in Google Scholar

29. Guevera M, Gines P, Jimenez W, Sort P, Fernandez Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114:336–43.10.1016/S0016-5085(98)70486-XSearch in Google Scholar

30. Fernandez-Rodriguez CM, Prada IR, Prieto J, Montuenga LM, Elssasser T, Quiroga J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998; 29:250–6.10.1016/S0168-8278(98)80010-XSearch in Google Scholar

31. Henriksen JH, Ring-Larsen H, Kanstrup IL, Fradsen E, Bendtsen F. Circulating norepinephrine and central hemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985; 20:1185–90.10.3109/00365528509089274Search in Google Scholar PubMed

32. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307:1552–7.10.1056/NEJM198212163072504Search in Google Scholar PubMed

33. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482–7.10.1016/0016-5085(88)90441-6Search in Google Scholar

34. Solis-Herruzo JA, Duran A, Favelza V, Castellano G, Madrid JL, Munoz-Yague MT, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5:167–73.10.1016/S0168-8278(87)80569-XSearch in Google Scholar

35. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34:1242–51.10.1053/jhep.2001.29200Search in Google Scholar

36. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002; 17:739–47.10.1046/j.1440-1746.2002.02778.xSearch in Google Scholar

37. Moller S, Emmeluth C, Henricksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 1993; 19:285–90.10.1016/S0168-8278(05)80584-7Search in Google Scholar

38. Uchihare M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992; 16:95–9.10.1002/hep.1840160117Search in Google Scholar

39. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327:1774–8.10.1056/NEJM199212173272502Search in Google Scholar

40. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347:1842–3.10.1016/S0140-6736(96)91667-0Search in Google Scholar

41. Kitamura H, Shimada R, Kobayashi A, Nomura K, Noike T, Harada H, et al. Plasma concentration of endothelin-1 does not reflect renal vasoconstriction as estimated by duplex ultrasonography in cirrhosis. Dig Dis Sci 1997; 42:542–5.10.1023/A:1018842925234Search in Google Scholar

42. Morrow JD, Moore KP, Award JA, Ravenscraft MD, Marini G, Badr K, et al. Marked overproduction of non-cyclo-oxygenase derived prostanoids (F2-isoprostane) in the hepatorenal syndrome. J Lipid Mediators 1993; 6:417–20.Search in Google Scholar

43. Holt S, Marley R, Goodier D, Harry D, Fernando B, Moore K. Oxidant stress and renal dysfunction in cholestasis. Gut 1998; 43:153.Search in Google Scholar

44. Holt S, Marley R, Fernando B, Harry D, Anand R, Goodier D, et al. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int 1999; 55:271–7.10.1046/j.1523-1755.1999.00252.xSearch in Google Scholar PubMed

45. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637–48.10.1053/gast.2000.20189Search in Google Scholar

46. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin, interleukin 8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18:41–6.Search in Google Scholar

47. Sheron N, Bird G, Goka J, Alexander G, Williams R. Elevated plasma interleukin 6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991; 84:449–53.Search in Google Scholar

48. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, et al. Acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998; 28:689–94.10.1002/hep.510280314Search in Google Scholar

49. Lopez-Talavera JC, Levitzki A, Martinez M, Gazit A, Esteban R, Guardia J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases NO production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 1997; 100:664–70.10.1172/JCI119578Search in Google Scholar

50. Lopez-Talavera JC, Merrill WW, Groszman RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal hypertensive rats. Gastroenterology 1995; 108:761–7.10.1016/0016-5085(95)90449-2Search in Google Scholar

51. Wilkinson SP, Willams R. Renin-angiotensin-aldosterone system in cirrhosis. Gut 1980; 21:545–54.10.1136/gut.21.6.545Search in Google Scholar

52. Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma renin level in hepatic cirrhosis: relation to functional renal failure. Am J Med 1970; 49:189–91.10.1016/S0002-9343(70)80074-2Search in Google Scholar

53. Cobden I, Shore A, Wilkinson R, Record CO. Captopril in the hepatorenal syndrome. J Clin Gastroenterol 1985; 7:354–60.10.1097/00004836-198508000-00018Search in Google Scholar

54. Schroeder ET, Anderson GH. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976; 9:511–9.10.1038/ki.1976.65Search in Google Scholar

55. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early advanced cirrhosis. Gastroenterology 2000; 118:565–72.10.1016/S0016-5085(00)70263-0Search in Google Scholar

56. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29:334–9.10.1002/hep.510290203Search in Google Scholar PubMed

57. Debarnardi-Venon D, Baretti C, Marzano A, Marzano A, Baronio M, Todros L, et al. Efficacy of irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension. Dig Dis Sci 2002; 47:401–4.10.1023/A:1013790610327Search in Google Scholar

58. Garcia-Tsao G. Angiotensin receptor antagonist in the pharmacological therapy: a caution. Gastroenterology 1999; 117:740–2.10.1016/S0016-5085(99)70472-5Search in Google Scholar

59. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991; 100:494–501.10.1016/0016-5085(91)90222-7Search in Google Scholar

60. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35–41.10.1002/hep.510270107Search in Google Scholar

61. Rodriguez-Perez F, Groszmann RJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clin North Am 1992; 21:15–40.10.1016/S0889-8553(21)00176-XSearch in Google Scholar

62. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941–8.10.1053/jhep.2002.35819Search in Google Scholar PubMed

63. Podolsky DK, Isselbacher KJ. Cirrhosis. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, editors. Harrison's principles of internal medicine, 11th ed. New York: McGraw-Hill, 1987.Search in Google Scholar

64. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154:201–5.10.1001/archinte.1994.00420020117013Search in Google Scholar

65. Linas SL, Schaefer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30:736–40.10.1038/ki.1986.249Search in Google Scholar PubMed

66. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944–53.10.1053/j.gastro.2005.09.024Search in Google Scholar PubMed

67. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20:362–9.10.1002/hep.1840200215Search in Google Scholar

68. Abuelo JG. Diagnosing vascular causes of renal failure. Ann Intern Med 1995; 123:601–14.10.7326/0003-4819-123-8-199510150-00007Search in Google Scholar PubMed

69. Brady HR, Singer GG. Acute renal failure. Lancet 1998; 346:1533–40.Search in Google Scholar

70. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334:1448–60.10.1056/NEJM199605303342207Search in Google Scholar PubMed

71. Heyman SN, Darmon D, Goldfarb M, Bitz H, Shina A, Rosen S, et al. Endotoxin-induced renal failure. A role for altered renal microcirculation. Exp Nephrol 2000; 8:266–74.10.1159/000020678Search in Google Scholar PubMed

72. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37:233–43.10.1053/jhep.2003.50084Search in Google Scholar PubMed

73. Klahr S, Miller SB. Acute oliguria. N Engl J Med 1998; 338:671–5.10.1056/NEJM199803053381007Search in Google Scholar PubMed

74. Porcel A, Diaz F, Rendon P, Marcias M. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162:323–8.10.1001/archinte.162.3.323Search in Google Scholar PubMed

75. Papadakis MA, Arieff A. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945–52.Search in Google Scholar

76. De Santo NG, Anastasio P, Loguercio C, Spitali L, Del Vecchio BC, Corvinelli M, et al. Creatinine clearance: an adequate marker of renal filtration in patients with early posthepatic cirrhosis (child A) without fluid retention and muscle wasting. Nephron 1995; 70:421–4.10.1159/000188639Search in Google Scholar PubMed

77. Woitas RP, Stoffel-Wagner B, Flommersfeld S, Poege U, Schiedermaier P, Klehr HU, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46:712–5.10.1093/clinchem/46.5.712Search in Google Scholar

78. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830–8.10.1038/ki.1985.205Search in Google Scholar PubMed

79. Herget-Rosenthal SH, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20:97–102.10.1159/000013564Search in Google Scholar PubMed

80. Orlando R, Musap M, Plebani M, Piccoli P, De Martin S, Florenai M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48:850–8.10.1093/clinchem/48.6.850Search in Google Scholar

81. Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood ED, editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia, PA: Saunders, 1999:1251–4.Search in Google Scholar

82. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38:20–7.Search in Google Scholar

83. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function – a review. Clin Chem Lab Med 1999; 37:389–95.10.1515/CCLM.1999.064Search in Google Scholar

84. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000; 54:203–9.Search in Google Scholar

85. Kyhse-Andersen J, Schimidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, et al. Serum cystatin C, determined by a rapid automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40:1921–6.10.1093/clinchem/40.10.1921Search in Google Scholar

86. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Greubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312–8.10.1038/ki.1995.40Search in Google Scholar

87. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101:875–81.10.1542/peds.101.5.875Search in Google Scholar

88. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998; 49:221–5.Search in Google Scholar

89. Stickle D, Cole B, Haock K, Hruska KA, Scott MG. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem 1998; 44:1334–8.10.1093/clinchem/44.6.1334Search in Google Scholar

90. Burkhardt H, Bojarsky G, Gretz N, Gladish R. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimation of true glomerular filtration rate in the elderly. Gerontology 2002; 48:104–6.10.1159/000052832Search in Google Scholar

91. Burkhardt H, Bojarsky G, Gladish R. Diagnostic efficiency of cystatin C and serum creatinine as markers of reduced glomerular filtration rate in the elderly. Clin Chem Lab Med 2002; 40:1135–8.10.1515/cclm.2002.199Search in Google Scholar

92. Gerbes AL, Gülberg V, Bizler M, Vogester M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50:106–10.10.1136/gut.50.1.106Search in Google Scholar

93. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311:81–9.10.1016/S0009-8981(01)00546-0Search in Google Scholar

Received: 2005-7-7
Accepted: 2006-1-3
Published Online: 2006-4-7
Published in Print: 2006-4-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Natriuretic peptides and evidence-based quality specifications
  2. Preanalytical variability: the dark side of the moon in laboratory testing
  3. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay
  4. Hepatorenal syndrome
  5. Modified Levey-Jennings charts for calculated laboratory tests
  6. Increased free malondialdehyde concentrations in smokers normalise with a mixed fruit and vegetable juice concentrate: a pilot study
  7. The exponentially weighted moving average (EWMA) rule compared with traditionally used quality control rules
  8. Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores
  9. Comparison of TEST 1 with SRS 100 and ICSH reference method for the measurement of the length of sedimentation reaction in blood
  10. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays
  11. Technical evaluation of the Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay
  12. Erythrocyte membrane Na+,K+-ATPase and Mg2+-ATPase activities in subjects with methylenetetrahydrofolate reductase (MTHFR) 677 C→T genotype and moderate hyperhomocysteinaemia. The role of L-phenylalanine and L-alanine
  13. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes
  14. Pyrosequencing protocol requiring a unique biotinylated primer
  15. Detection of antibodies against 60-, 65- and 70-kDa heat shock proteins in paediatric patients with various disorders using Western blotting and ELISA
  16. Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometry
  17. Time-level relationship between indicators of oxidative stress and Glasgow Coma Scale scores of severe head injury patients
  18. Stepwise strategies in analysing haematuria and leukocyturia in screening
  19. Elevation of serum cerebral injury markers correlates with serum choline decline after coronary artery bypass grafting surgery
  20. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study
  21. Release of anandamide from blood cells
  22. Rapid decrease in plasma D-lactate as an early potential predictor of diminished 28-day mortality in critically ill septic shock patients
  23. Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry
  24. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases
  25. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens
  26. Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome
  27. The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker?
  28. Is cystatin C a reliable renal marker in trauma?
  29. On the independence of intraindividual reference values
  30. Sixth International Symposium on Molecular Diagnostics, Graz, Austria, May 25-27, 2006
https://doi.org/10.1515/CCLM.2006.062
Keywords for this article
cystatin C; hepatorenal syndrome; laboratory assessment

Articles in the same Issue

  1. Natriuretic peptides and evidence-based quality specifications
  2. Preanalytical variability: the dark side of the moon in laboratory testing
  3. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay
  4. Hepatorenal syndrome
  5. Modified Levey-Jennings charts for calculated laboratory tests
  6. Increased free malondialdehyde concentrations in smokers normalise with a mixed fruit and vegetable juice concentrate: a pilot study
  7. The exponentially weighted moving average (EWMA) rule compared with traditionally used quality control rules
  8. Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores
  9. Comparison of TEST 1 with SRS 100 and ICSH reference method for the measurement of the length of sedimentation reaction in blood
  10. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays
  11. Technical evaluation of the Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay
  12. Erythrocyte membrane Na+,K+-ATPase and Mg2+-ATPase activities in subjects with methylenetetrahydrofolate reductase (MTHFR) 677 C→T genotype and moderate hyperhomocysteinaemia. The role of L-phenylalanine and L-alanine
  13. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes
  14. Pyrosequencing protocol requiring a unique biotinylated primer
  15. Detection of antibodies against 60-, 65- and 70-kDa heat shock proteins in paediatric patients with various disorders using Western blotting and ELISA
  16. Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometry
  17. Time-level relationship between indicators of oxidative stress and Glasgow Coma Scale scores of severe head injury patients
  18. Stepwise strategies in analysing haematuria and leukocyturia in screening
  19. Elevation of serum cerebral injury markers correlates with serum choline decline after coronary artery bypass grafting surgery
  20. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study
  21. Release of anandamide from blood cells
  22. Rapid decrease in plasma D-lactate as an early potential predictor of diminished 28-day mortality in critically ill septic shock patients
  23. Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry
  24. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases
  25. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens
  26. Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome
  27. The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker?
  28. Is cystatin C a reliable renal marker in trauma?
  29. On the independence of intraindividual reference values
  30. Sixth International Symposium on Molecular Diagnostics, Graz, Austria, May 25-27, 2006
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 15.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.062/html
Scroll to top button